Dr. Hanna is a staff cardiologist in the Section of Heart Failure and Cardiac Transplantation Medicine in the Sydell and Arnold Miller Family Heart & Vascular Institute. He is Director of the Heart Failure Intensive Care Unit and Co-Director of the Amyloid Program. Dr. Hanna's specialty interests include cardiomyopathy, heart failure, heart transplantation and mechanical circulatory assist devices, pulmonary hypertension, and cardiac amyloid.
He is board certified in Internal Medicine, Cardiology, and Advanced Heart Failure and Transplant by the American Board of Internal Medicine. Dr. Hanna performs right and left heart catheterization as well as endomyocardial biopsy.
Dr. Hanna is a native of Cleveland and grew up in Pepper Pike, Ohio. He received his Bachelor of Arts degree from Cornell University in Ithaca, New York where he majored in Psychology. He received his Medical Degree from The Ohio State University and went on to do his Internal Medicine training at the Baylor College of Medicine in Houston, Texas where he received the Outstanding Medical Resident Teacher Award. He came back to Cleveland to do his Cardiology Fellowship training at Case Western Reserve University, MetroHealth Campus where he was appointed Chief Cardiovascular Fellow. He completed his training with a one year Advanced Fellowship in Heart Failure and Cardiac Transplantation at the Cleveland Clinic. He was appointed as a staff cardiologist in 2006.
Dr. Hanna is a member of Heart Failure Society of America, American Heart Association, American College of Cardiology, International Society for Heart and Lung Transplantation, and the International Society of Amyloidosis.
Current publications include:
- Hanna MA, Tang WH, Teo BW,et al. Extracorporeal ultrafiltration vs. conventional diuretic therapy in advanced decompensated heart failure. Congest Heart Fail. 2012 Jan;18(1):54-63.
- Eckman PM, Hanna M, Taylor DO, Starling RC, Gonzalez-Stawinski GV. "Management of the sensitized adult heart transplant candidate". Clin Transplant. 2010 Nov;24(6):726-34
- Wong RC, Abrahams Z, Hanna M, Pangrace J, Gonzalez-Stawinski G, Starling R, Taylor D. "Tricuspid regurgitation after cardiac transplantation: an old problem revisited". J Heart Lung Transplant. 2008 Mar;27(3):247-52.
- Hanna M, Finkelhor RS, Shaw WF, Bahler RC. "Extent of right and left ventricular focal wall-motion abnormalities in differentiating transient apical ballooning syndrome from apical dysfunction as a result of coronary artery disease". J Am Soc Echocardiogr. 2007 Feb;20(2):144-50.
Cardiomyopathy, heart failure, heart transplantation, ventricular assist device, myocardial biopsy, cardiac catheterization, cardiac amyloid, pulmonary hypertension
Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.
To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. The Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists
receive or have the right to receive royalties or (iv) its physicians/scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, the Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.
As of 4/29/2013, Dr. Hanna has reported no financial relationship with industry that is applicable to this listing. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by the Cleveland Clinic. To learn more about the Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.
Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers’ discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias. * Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.